@article{813d02f9be4748b4820651fec79dd542,
title = "Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study",
keywords = "dexamethasone, lenalidomide, multiple myeloma, pembrolizumab, relapsed/refractory",
author = "Mateos, {Maria Victoria} and Orlowski, {Robert Z.} and Ocio, {Enrique M.} and Paula Rodr{\'i}guez-Otero and Donna Reece and Philippe Moreau and Nikhil Munshi and Avigan, {David E.} and Siegel, {David S.} and Razi Ghori and Farooqui, {Mohammed Z.H.} and Patricia Marinello and Jesus San-Miguel",
note = "Funding Information: The authors thank the patients and their families and caregivers for participating in the study. The authors also thank Tammy Wolfsohn, Michael Bossio, Mena Tookhi, Michelle Smith, Jason Liao, Valeria Noriega, Paula Liscio, Ekta Kapadia and Roger Dansey (employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) for their contributions to the development of the manuscript. Medical writing and/or editorial assistance was provided by Doyel Mitra, PhD, and Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.",
year = "2019",
doi = "10.1111/bjh.15946",
language = "English (US)",
volume = "186",
pages = "e117--e121",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",
}